The European radioimmunoassay market retains its relevance for endocrinology, oncology, therapeutic drug monitoring, pharmacology research, and highly sensitive biomarker detection applications. While faced with increasing competition from alternative non-radioactive techniques, RIA still proves to be a useful technique when extremely precise determination of hormones, antigens, drugs, and other substances in minute amounts is needed. The presence of good infrastructure for clinical research, pathology laboratories, and nuclear medicine, along with investments into precise diagnostics, enables the continued use of RIA in Europe.
The Europe Radioimmunoassay Market accounted for approximately 30.00% of global revenue in 2025, with a market value of around USD 0.36 billion. The regional market is projected to reach approximately USD 0.56 billion by 2035, expanding at a CAGR of around 4.50% from 2026 to 2035. Globally, the Radioimmunoassay Market was valued at USD 1.20 billion in 2025 and is expected to reach USD 1.93 billion by 2035, registering a CAGR of 4.89%.
Gain Actionable Intelligence on the Radioimmunoassay Market – Request a Free Sample Report
Precision Diagnostics and Research Sustain European RIA Demand
The Europe RIA market is driven by advanced diagnostic technology, high testing volumes, research-oriented healthcare facilities and already existing nuclear medicine techniques. Germany, France, U.K., Italy, Switzerland and other Western European countries have developed good capacity in clinical laboratory services and biomedical research to facilitate special diagnostic tests.
Clinical laboratories occupied about 42.7% of the market, which still remains the dominant end-user segment since they conduct high volumes of diagnostic tests through quality control measures. Pharmaceutical and biotech companies are increasingly using RIA in drug development, pharmacokinetics study, biomarker validation and clinical trail. Personalized medicine is also providing new possibilities. RIA helps to conduct very sensitive tests on drug concentrations, hormone therapy, cancer markers and immune response in situations when even small biological differences may affect therapeutic options.
Companies Supporting Europe’s Radioimmunoassay Market
Berthold Technologies GmbH & Co. KG
Berlin-based Berthold Technologies manufactures instruments and devices involved in diagnostic, research, and life science applications, which include measurement systems that have applications in radioimmunoassays. The company’s emphasis on accuracy and automation in their products aims at providing solutions for hormone analysis, biomarker and drug testing. In 2024, Berthold Technologies introduced the RIAStar, an automation system for RIA processes. This instrument represents growing needs among European labs for systems that can help to increase efficiency and standardization of assays, throughput and maintain accuracy inherent to RIA processes.
IBL International
IBL International, a company headquartered in Germany, offers a wide range of immunoassay products which are utilized for clinical diagnostics and research purposes and which include radioimmunoassay kits for hormones, tumor markers, and autoimmune diseases. Emphasis of the company on the high degree of sensitivity of assays, reproducibility of the results, quality control, and laboratory efficiency explains why there is such a demand for its products from the specialized laboratories of Europe. In 2024, IBL International released RIA Connect, a cloud-based digital solution meant to improve quality control and data management of radioimmunoassays.
DiaSorin S.p.A.
DiaSorin is one of the well-known diagnostic firms with a wealth of experience in immunodiagnostics and laboratory technology. The firm’s location in Italy gives it an edge due to its proximity to the well-developed diagnostic structure in Europe, which is increasingly becoming concerned with sensitive biomarkers, automation, and laboratory testing. While the laboratories still struggle to balance between traditional radioimmunoassays and novel immunodiagnostic tests, firms that excel in assays development and have laboratory platforms become quite significant.
Europe Radioimmunoassay Outlook Through 2035
The Europe radioimmunoassay market is predicted to grow at a consistent pace till 2035 on account of endocrine testing, cancer studies, pharmacokinetic studies, pharmaceutical development, and personalized medicine. Increasing costs associated with regulatory compliance concerning the handling of radioactive substances, waste management, storage facilities, and safety precautions will persist.
Competition from ELISA, chemiluminescent immunoassays, and other non-radioactive technologies will further restrict the application of RIA. Still, RIA will be significant for applications that require extremely sensitive quantitative measurements. With the Europe Radioimmunoassay Market reaching a revenue of $0.56 billion by 2035, automation, radioisotope handling, integration with digital laboratories, and specialty applications of biomarkers will ensure continued demand for RIA in Europe.
